At the JP Morgan Healthcare Conference in San Francisco, South Korea’s Celltrion (Kosdaq: 068270) outlined details of its business plan for 2019, confirming the firm’s main focus will be on the development of a subcutaneous form of CT-P13, a biosimilar version of the immunological therapy infliximab.
Developed by Johnson & Johnson (NYSE: JNJ), the reference version of infliximab is marketed as Remicade.
A subcutaneous version would give people the opportunity to self-inject, allowing them to receive treatment at home.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze